Heart-rate adjustment of transcatheter haemodynamics improves the prognostic evaluation of paravalvular regurgitation after transcatheter aortic valve implantation

Hasan Jilaihawi*, MD; Tarun Chakravarty, MD; Takahiro Shiota, MD; Asim Rafique, MD; Kenji Harada, MD; Kentaro Shibayama, MD; Niraj Doctor, MD; Mohammad Kashif, MD; Mamoo Nakamura, MD; James Mirocha, MS; Tejas Rami, MD; Kazuaki Okuyama, MD; Wen Cheng, MD; Omar Sadrudden, MD; Robert Siegel, MD; Raj R. Makkar, MD

Cedars-Sinai Heart Institute, Los Angeles, CA, USA

This paper also includes accompanying supplementary data published online at: http://www.pcoronline.com/eurointervention/87th_issue/91

Abstract

**Aims:** Paravalvular aortic regurgitation (PVAR) after balloon-expandable transcatheter aortic valve implantation (TAVI) remains difficult to quantify, and the utility of the AR index (ARi) to create a composite aortic insufficiency (CAI) score was an important advance. Heart rate (HR) influences the ARi but the clinical relevance of this phenomenon remains poorly appreciated. We sought to validate a new composite heart-rate-adjusted haemodynamic-echocardiographic aortic insufficiency (CHAI) score in the prognostic evaluation of PVAR after balloon-expandable TAVI.

**Methods and results:** The severity of PVAR was assessed immediately post TAVI by transoesophageal echocardiography (TOE) with simultaneous assessment of transcatheter haemodynamics. A total of 303 patients were studied. The CHAI score, incorporating the HR-adjusted diastolic-delta (HRA-DD, the difference between left ventricular and aortic diastolic pressures/HR*80), had a greater discriminatory value for one-year mortality than both PVAR by TOE (p=0.0018) and the previously proposed CAI score, based on the ARi without HR adjustment (p=0.0029). The CHAI score also better stratified percentage increases in left ventricular systolic chamber dimensions at one month and serum natriuretic peptide levels at one to three months.

**Conclusions:** Prognostication of PVAR in the intermediate range of echocardiographic severity remains unreliable and is greatly enhanced by the integration of heart-rate-adjusted transcatheter haemodynamics.

*Corresponding author: Cedars-Sinai Heart Institute, 127 S. San Vicente Blvd, Suite A3600, Los Angeles, CA, 90048, USA. E-mail: hasanjilaihawi@gmail.com


**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI</td>
<td>aortic insufficiency</td>
</tr>
<tr>
<td>AoDBP</td>
<td>aortic diastolic blood pressure</td>
</tr>
<tr>
<td>AoSBP</td>
<td>aortic systolic blood pressure</td>
</tr>
<tr>
<td>AR</td>
<td>aortic regurgitation</td>
</tr>
<tr>
<td>ARi</td>
<td>aortic regurgitation index</td>
</tr>
<tr>
<td>CHAI score</td>
<td>composite heart-rate-adjusted haemodynamic-echocardiographic aortic insufficiency score</td>
</tr>
<tr>
<td>DD</td>
<td>diastolic delta</td>
</tr>
<tr>
<td>HR</td>
<td>heart rate</td>
</tr>
<tr>
<td>HR-ARi</td>
<td>heart-rate-adjusted aortic regurgitation index</td>
</tr>
<tr>
<td>HRA-DD</td>
<td>heart-rate-adjusted diastolic delta</td>
</tr>
<tr>
<td>LVEDP</td>
<td>left ventricular end-diastolic pressure</td>
</tr>
<tr>
<td>PVAR</td>
<td>paravalvular aortic regurgitation</td>
</tr>
<tr>
<td>TAVI</td>
<td>transcatheter aortic valve implantation</td>
</tr>
<tr>
<td>TAVR</td>
<td>transcatheter aortic valve replacement</td>
</tr>
<tr>
<td>TOE</td>
<td>transoesophageal echocardiography</td>
</tr>
</tbody>
</table>

**Introduction**

It has been established that paravalvular aortic regurgitation (PVAR) is an important complication after transcatheter aortic valve implantation (TAVI) and is associated with increased mortality. Echocardiography is presently the modality of choice in the comprehensive periprocedural assessment of post-TAVI aortic regurgitation (AR). It has been employed in core lab evaluations of this complication and can evaluate both severity and mechanism, distinguishing valvular from paravalvular (PV) AR. However, the quantification of PVAR using echocardiography is challenging, particularly in the intermediate range of severity; indeed, the survival of patients with mild and moderate-severe PVAR was similar in the PARTNER trial. Moreover, the SAPIEN device (Edwards Lifesciences, Irvine, CA, USA) in the PARTNER IIB trial showed twice the rate of paravalvular AR compared with the PARTNER IIB trial, with the only real change being the different core lab for echocardiographic assessment between the studies. This heterogeneity of assessment has important implications in cross-trial and cross-device comparisons.

Recently, the aortic regurgitation index (ARi) has offered incremental value to angiographic assessment in the risk stratification of PVAR. However, it is known that heart rate (HR) can influence diastolic transcatheter haemodynamics and can therefore dramatically alter the ARi, which does not take into account the influence of HR, and has resulted in considerable discrepancies in isolated cases in our large TAVI practice. We hypothesised that a composite heart-rate-adjusted haemodynamic-echocardiographic aortic insufficiency (CHAI) score would improve prognostication of PVAR evaluated by Valve Academic Research Consortium-2 (VARC-2) derived transoesophageal echocardiography (TOE) grading alone and also a composite haemodynamic-echocardiographic aortic insufficiency without heart rate adjustment (CAI) score, in line with a recently proposed methodology.

**Methods**

**PATIENT POPULATION, ASSESSMENT AND PROCEDURE**

All patients had severe symptomatic aortic stenosis (AS) and were treated in a single centre with balloon-expandable TAVI (Edwards SAPIEN/SAPIEN XT; Edwards Lifesciences), performed predominantly under fluoroscopic guidance, as has been previously described. All patients studied had simultaneous transcatheter transaortic haemodynamic pressures measured post TAVI, with a multipurpose catheter placed across the transcatheter valve into the left ventricular cavity and a pigtail catheter placed in the aortic root above the transcatheter valve. If an additional manoeuvre was performed, such as valve-in-valve or post-dilatation, haemodynamic pressures were recorded after that additional intervention.

Patients also had periprocedural TOE imaging for procedural guidance and post-TAVI evaluation of valvular function. TOE was performed using the iE33 xMATRIX Ultrasound System for Echocardiography (Philips Medical Systems Inc., Bothell, WA, USA). Within the confines of available transcatheter haemodynamic data, patients were consecutive and all were followed beyond one year after the index procedure (all patients had at least one year of post-procedural follow-up).

Sizing for TAVI was made at the operator’s discretion, using data from all available imaging modalities at the time of the procedure, with a reliance on traditional cut-offs for annular size by 2D-TOE measurement (D2D,TOE) early in the series, and a later reliance predominantly on cross-sectional measurements by computed tomography or three-dimensional (3D) echocardiography.

**POST-TAVI PVAR, THE ARI AND HEART RATE**

Post-TAVI PVAR was assessed retrospectively using VARC-2 criteria, which include both semiquantitative and quantitative parameters, with comprehensive periprocedural TOE examinations reviewed retrospectively. This was performed by one of two physician readers experienced in the assessment of TAVI echocardiograms, blinded to the periprocedural TOE report, annular measurements, clinical, angiographic and haemodynamic data, to retain complete objectivity. Reproducibility was excellent; for intraobserver agreement for the assessment of significant PV regurgitation, the kappa statistic was 0.77 (p<0.001), and for inter-observer agreement the kappa was also 0.77 (p<0.001). The transcatheter ARi index was calculated according to the following formula: ([DBP-LVEDP]/SBP)×100. An ARi <25 was regarded as clinically significant. The heart rate (HR) was derived from the simultaneous electrocardiogram using the R-R interval associated with the haemodynamic waveform studied with stable electrocardiogram and haemodynamics for at least three beats. This was used to generate the heart-rate-adjusted diastolic delta (HR-DD), calculated as (DD/HR×80), where diastolic delta was (aortic diastolic pressure minus left ventricular end-diastolic pressure).

Editorial, see page 371
**STATISTICAL ANALYSIS**
Statistical analyses were made using SPSS software (PASW v18; SPSS Inc., Chicago, IL, USA) and MedCalc v12.7.0 (MedCalc, Ostend, Belgium). Normality of distributions for continuous variables was tested using the Shapiro-Wilk test. The Fisher’s exact test was used for categorical variables compared across independent groups. For normally distributed continuous variables compared across independent groups, an independent samples t-test was employed. For non-normally distributed continuous variables compared across independent groups, a Mann-Whitney U test was used.

Other haemodynamic parameters were also studied for their predictive value for one-year mortality using receiver operator characteristic (ROC) curve analysis. The haemodynamic parameter most predictive of survival was combined with TOE AR grade data to generate an optimal composite (TOE/haemodynamic) heart-rate-adjusted AI (CHAI) score. This was based on the TOE AR grade if there was none/trivial (graded CHAI 0) or severe AR (graded CHAI 3) on TOE, or on a combination of TOE and heart-rate-adjusted transcatheter haemodynamics if there was intermediate AR (mild or moderate) (Figure 1). Intermediate PVAR was graded as not significant if the HR-DD was ≥25 (CHAI score 1) and significant if the HR-DD was <25 (CHAI score 2). A composite AI (CAI) score, recently proposed by the Bonn group, incorporating the ARi without heart rate adjustment has suggested that ARi (<25) be used to stratify mild AR for significance (Figure 1). Other details of statistical analysis performed can be found in Online Appendix 1.

**Results**

**BASELINE AND PROCEDURAL CHARACTERISTICS**
A total of 303 patients were studied. Median age was 86 (interquartile range [IQR], 80-90) and mean aortic valve gradient was 43 mmHg (IQR 41-52). Baseline and procedural data are shown in Table 1.

**OPTIMAL DIASTOLIC HAEMODYNAMIC INDICES FOR PROGNOSTICATION**
We further studied transcatheter haemodynamic parameters related to survival. A comparison of the individual components of the ARi (AoDBP, LVEDP and AoSBP) showed the “diastolic delta” (DD, the difference between aortic diastolic and LV end-diastolic pressure) was also useful for stratification of survival.

---

A. Bonn CAI score

- **TEE AR assessment post TAVR**
  - **Confirm PV leak**
  - **Transcatheter haemodynamic assessment**
    - **Aortic regurgitation index** = (AoDBP-LVEDP)/AoSBP
    - **>25**
      - **CAI score 0**
      - **No further intervention**
    - **CAI score 1**
      - **Evasive manoeuvres to rectify leak**
        - (1) Post-dilatation
        - (2) TV-in-TV (diffuse PV leak)
        - (3) PV leak closure (focal PV leak)
        - (4) Emergent surgery (if percutaneous methods fail)
    - **≤25**
      - **CAI score 2**
      - **Evasive manoeuvres to rectify leak**
        - (1) Post-dilatation
        - (2) TV-in-TV (diffuse PV leak)
        - (3) PV leak closure (focal PV leak)
        - (4) Emergent surgery (if percutaneous methods fail)
      - **CAI score 3**

B. LA CHAI score

- **TEE AR assessment post TAVR**
  - **Confirm PV leak**
  - **Transcatheter haemodynamic assessment**
    - **Heart-rate-adjusted diastolic delta** = (AoDBP-LVEDP)/HR*80
    - **>25**
      - **CHAI score 0**
      - **No further intervention**
    - **CHAI score 1**
      - **Evasive manoeuvres to rectify leak**
        - (1) Post-dilatation
        - (2) TV-in-TV (diffuse PV leak)
        - (3) PV leak closure (focal PV leak)
        - (4) Emergent surgery (if percutaneous methods fail)
    - **≤25**
      - **CHAI score 2**
      - **Evasive manoeuvres to rectify leak**
        - (1) Post-dilatation
        - (2) TV-in-TV (diffuse PV leak)
        - (3) PV leak closure (focal PV leak)
        - (4) Emergent surgery (if percutaneous methods fail)
      - **CHAI score 3**

Figure 1. Stratification of intermediate severity aortic regurgitation using the Bonn CAI score (A) and the LA CHAI score (B). There are two principal differences. Firstly, stratification of moderate AR is not performed with the CAI score, whereas the CHAI score does not propose intervention with moderate AR which is not haemodynamically significant. Secondly, the CAI score does not adjust for heart rate, whereas the CHAI score does.
## Table 1. Baseline and procedural characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n=303</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, median (IQR)</td>
<td>86 (80-90)</td>
</tr>
<tr>
<td>LES, %</td>
<td>24.78 (15.54-35.3)</td>
</tr>
<tr>
<td>STS mortality, %</td>
<td>10.3 (8.4-12.1)</td>
</tr>
<tr>
<td>Height, cm</td>
<td>165.1 (157-173)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>71 (61-84)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>145 (48.3)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>112 (37.6)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>264 (88.6)</td>
</tr>
<tr>
<td>Prior PCI</td>
<td>111 (37.2)</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>104 (34.8)</td>
</tr>
<tr>
<td>Prior CVA</td>
<td>67 (22.5)</td>
</tr>
<tr>
<td>Baseline Cr &gt;2 mg/dL</td>
<td>43 (14.4)</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>158 (53.0)</td>
</tr>
<tr>
<td>Aortic annulus diameter on 2D TEE, mm, median (IQR)</td>
<td>22 (20-23)</td>
</tr>
<tr>
<td>Aortic annulus perimeter on contrast CT</td>
<td>76.3 (70.6-82.6)</td>
</tr>
<tr>
<td>Agatston score, AU</td>
<td>3,409 (2,319-4,820)</td>
</tr>
<tr>
<td>Baseline aortic mean gradient, mmHg</td>
<td>43 (41-52)</td>
</tr>
<tr>
<td>Baseline aortic peak velocity, m/s</td>
<td>4.23 (3.93-4.65)</td>
</tr>
<tr>
<td>LVEF baseline, %</td>
<td>62 (50-69)</td>
</tr>
<tr>
<td>Baseline severe MR, n (%)*</td>
<td>49 (17.3)</td>
</tr>
<tr>
<td>Baseline AR grade ≥moderate*</td>
<td>37 (12.3)</td>
</tr>
<tr>
<td>Valve type</td>
<td>SAPIEN, n (%)</td>
</tr>
<tr>
<td></td>
<td>SAPIEN XT</td>
</tr>
<tr>
<td>Valve size</td>
<td>23 mm</td>
</tr>
<tr>
<td></td>
<td>26 mm</td>
</tr>
<tr>
<td>Access</td>
<td>Transfemoral</td>
</tr>
<tr>
<td></td>
<td>Transapical</td>
</tr>
</tbody>
</table>

*on transthoracic echocardiography. LES: Logistic EuroSCORE I

---

pressure) to have the greatest predictive value for one-year mortality (Online Table 1). This improved further with simple heart rate adjustment (Diastolic delta/HR*80). Simple heart rate adjustment of the DD dramatically improved the stratification of one-year survival (Online Figure 1). The heart-rate-adjusted diastolic delta (HRA-DD) removed the substantial influence of bradycardia on transcatheter haemodynamic parameters (Figure 3) and was therefore the preferred haemodynamic parameter. The highest sum of sensitivity and specificity for one-year mortality by the HRA-DD occurred at a threshold of ≤24.8. The cut-off of 25 was therefore retained for simplicity. Of note, although the AoSBP is the denominator of the ARi (and hence a lower AoSBP would increase the ARi), lower AoSBP was associated with higher one-year mortality (Online Table 1).

### A COMPOSITE HAEMODYNAMIC-ECHOCARDIOGRAPHIC AORTIC INSUFFICIENCY ASSESSMENT (CAI)

Composite haemodynamic-echocardiographic assessment using the CAI score, in line with the methodology proposed by the Bonn group, stratified survival somewhat better than TOE alone.
INCREMENTAL PROGNOSTIC VALUE OF THE CHAI SCORE: SURVIVAL

Since the extremes of PV AR by TOE stratified survival well, transcatheater haemodynamics were not applied for these patients, who retained their TOE grade separation in the composite

TOE-haemodynamic grading (zero for none/trivial and three for TOE graded AR ≥3). Given the difficulty in assessing “intermediate” (mild or moderate) and the superimposed outcomes seen in this range (Figure 2), the simple heart rate adjustment of the diastolic delta (Diastolic delta/HR*80) was applied to these patients and those with a value ≥25 were graded 1 in the CHAI score and those with a value <25 were graded 2.

The CHAI score was compared to the CAI score and TOE alone for discrimination of one-year mortality using ROC curve analysis (Figure 4): the composite assessment without heart rate adjustment (Bonn CAI score) was not superior to TOE (Bonn CAI score AUC 0.69, 95% CI: 0.63 to 0.74 vs. TOE AUC 0.67, 95% CI: 0.62 to 0.72, p for difference 0.30). In contrast, the composite assessment with heart rate adjustment (Los Angeles [LA] CHAI score) was superior to both TOE (LA CHAI score AUC 0.73, 95% CI; 0.68 to 0.78 vs. TOE AUC 0.67, 95% CI: 0.62 to 0.72, p for difference 0.002) and the Bonn CAI score (LA CHAI score AUC 0.73, 95% CI: 0.68 to 0.78 vs. Bonn CAI score AUC 0.69, 95% CI: 0.63 to 0.74, p for difference 0.006).

A scrutiny of Kaplan-Meier survival curves based on stratification of PVAR by the respective composite haemodynamic-echo-cardiographic methodologies demonstrated an improved prognostic stratification of “clinically significant” (score 2 or 3) vs. “not clinically significant” but >trivial (score 1) PVAR with the LA methodology vs. the Bonn methodology, demonstrating the incremental value of heart rate adjustment (Figure 5).

THE CHAI SCORE, LEFT VENTRICULAR CHAMBER DIMENSIONS AND NATRIURETIC PEPTIDES

A CHAI score >1 vs. ≤1 stratified the one-month left ventricular end-systolic dimension expressed as a percentage of baseline:
this was 106% baseline (IQR 93.8-119.2) vs. 96% baseline (IQR 88-110.2), respectively (p=0.019). Neither AR ≥moderate vs. <moderate by VARC-2 TOE criteria (p=0.19) nor CAI >1 vs. ≤1 (p=0.20) stratified this parameter.

Percentage change in serum natriuretic peptide (NPA) levels at one to three months post procedure relative to baseline did not differ significantly in those with AR ≥moderate vs. <moderate by TOE (p=0.12) or in those with CAI >1 vs. ≤1 (p=0.15). In contrast, the percentage change in serum NPA levels at one to three months post procedure relative to baseline was better stratified by CHAI score (for CHAI score >1 vs. ≤1 NPA levels at one to three months were 104.4% of baseline [IQR 49.5-239.1] vs. 78.5% of baseline [IQR 53.7-130.7]), although this was of borderline statistical significance (p=0.051).

**COEXISTING CONDITIONS INFLUENCING DIASTOLOGY**

Both mitral regurgitation (MR) and left ventricular dysfunction can influence LVEDP and potentially also the DD and CAI/CHAI scores. Baseline severe MR was weakly correlated to baseline LVEDP (p=0.014, r=0.15) but not post-TAVI LVEDP (p=0.46) or significant CHAI score (p=0.63). Lower baseline LVEF was weakly correlated to baseline LVEDP (p=0.010, r=0.15) as well as post-TAVI LVEDP (p=0.043, r=0.12) and significant CHAI score (p=0.037, r=0.12).

**MULTIVARIABLE ANALYSIS OF ONE-YEAR MORTALITY AND THE OPTIMAL PROGNOSTICATOR FOR PVAR**

In univariate analysis, variables related to one-year mortality to a p≤0.1 included age, male sex, baseline creatinine ≥2 mg/dL, pulmonary disease, STS score, baseline peak velocity, heart rate, LV ejection fraction, PVAR ≥moderate by TOE, CAI score ≥2 and CHAI score ≥2. In the multivariable model without CAI and CHAI scores, PVAR ≥moderate by TOE was a statistical predictor of one-year mortality (p=0.072) whereas male sex (OR 4.11, 95% CI: 1.93-8.76, p<0.0001), baseline creatinine ≥2 mg/dL (OR 2.78, 95% CI: 1.29-5.98, p=0.009) and HR (per 10 beats-per-minute increase in HR, OR 1.22, 95% CI: 1.02-1.45, p<0.030) were significant independent predictors. The CAI score was a significant independent risk factor for death when it was added to the model (OR 3.31, 95% CI: 1.60-6.84, p=0.001). In turn, addition of the CHAI score to this model rendered the CAI score non-significant (p=0.12), whereas the CHAI score emerged as the dominant predictor of death at one year (OR 6.5, 95% CI: 3.1-13.8, p<0.001) when the three competing variables assessing PVAR were all included in the model.

**Discussion**

In this study, we found a substantial incremental prognostic value in the application of a composite heart-rate-adjusted haemodynamic-echocardiographic aortic insufficiency (CHAI) score of paravalvular regurgitation after balloon-expandable TAVI. This builds upon the crucial concept of incorporating transcatheter haemodynamics into the traditional assessment of PVAR. We found that the CHAI score could also stratify changes in left ventricular cavity dimensions at follow-up, and to some extent changes in serum natriuretic peptides, whereas TOE and a composite score without heart rate adjustment could not. Importantly, this assessment took into account the substantial influence that heart rate has on transcatheter haemodynamics, which has thus far been neglected. A simple illustration of the influence of heart rate on transcatheter haemodynamics can be demonstrated with transvenous pacing where the ARi was <25 or ≥25 in the same patient when the heart rate was lower or higher, respectively (Figure 6).

**ASSESSMENT MODALITIES FOR PARAVALVULAR REGURGITATION AND THE LACK OF A GOLD STANDARD FOR QUANTIFICATION**

There remains the lack of a gold standard for the quantification and reliable prognostication of PVAR. Quantification with MRI has potential but can be time-consuming and has not been applied routinely. Furthermore, it cannot provide immediate periprocedural information that can be used to guide emergent therapy. Many centres, particularly those employing self-expanding TAVI devices, perform immediate post-procedural angiography, which can be highly observer-dependent, given its reliance on the subjective interpretation of superimposed images.

The ARi was an important step forward in the prognostic evaluation of AR. However, the frequency of patients with an ARi ≥25 is very high (57.4% in the present series and 34.2% and 42.6% in two recent series), and often co-exists with no/trivial AR, particularly in the presence of relative bradycardia, which is not infrequently seen after TAVI. We found baseline LVEF to be weakly correlated to LVEDP pre and post TAVI as well as the CHAI score. The CHAI score was a significant independent predictor of mortality, even correcting for baseline LVEF. The presence of LV dysfunction may influence patient tolerance for even mild degrees of AR and hence its influence on the CHAI score may embellish rather than limit the prognostic value of this new composite parameter.

Echocardiography is the mainstay for the identification of paravalvular regurgitation. However, the quantitative assessment of PVAR by TOE remains challenging and, although grading severe or trivial AR is straightforward, intermediate severity AR has significant inter-observer variability. The difficulties involved are reflected by the fact that, despite a rigorous core lab-based methodology, the PARTNER trial demonstrated equally poor outcomes in patients with PVAR graded as mild vs. those graded as moderate-severe. Similarly, we observed limited discriminatory value of TOE when the AR was in the intermediate range, such that the Kaplan-Meier curves for mild and moderate PVAR were almost identical (Figure 2). The simplification of assessment by TOE to none/trivial, intermediate and severe, with intermediate further stratified with heart-rate-adjusted haemodynamics is both conceptually appealing and supported by the data presented here.
Undoubtedly, PV AR is best avoided through judicious case selection and the application of cross-sectional measures of TAVI sizing. Moreover, the advent of new TAVI devices such as the SAPIEN 3 (Edwards Lifesciences) appears to have substantially reduced the frequency of moderate PV AR by echocardiographic assessment but, even with these advances, there remains a substantial percentage of patients with mild PV AR which could still be prognostically significant, particularly with the treatment of younger, lower surgical risk TAVI candidates. When PV AR occurs, clinicians have several treatment modalities at their disposal during the procedure, including post-dilatation, transcatheter valve-in-valve therapy (TV-in-TV), percutaneous PV leak closure and emergent surgery. Each of these therapies potentially carries additional risk that should be weighed against its potential benefit. Post-dilatation, although often effective in reducing the severity of PVAR, is not only associated with higher rates of clinical stroke but is also an important risk factor for the rare but generally fatal complication of annular rupture. Moreover, transcatheter valve-in-valve therapy (TV-in-TV), despite being effective acutely, is associated with higher rates of pacemaker implantation and increased late cardiac mortality. For percutaneous PV leak closure, although well studied after surgical AVR, there are limited efficacy data in PVAR, where, unlike after SAVR, the leaks are often multifocal. The CHAI score provides an important foundation for stratifying patients who carry the poorest prognosis without further intervention and who thus have the greatest clinical need to justify immediate therapy.

**STUDY LIMITATIONS AND FUTURE DIRECTIONS**

This was a single-centre retrospective study and its findings require further validation in other prospective series. Although the expert TOE reviewers were blinded to clinical and haemodynamic data, there was no formal core lab evaluation of PV AR by TOE. We did not explore the diastolic:systolic velocity time integral ratio, which is another parameter that may take into account the effects of heart rate on transcatheter haemodynamics and may also be of interest. Although the CHAI score identifies those patients whose prognosis is favourable and who are thus unlikely to need further intervention, an unfavourable CHAI score does not mean that further manoeuvres to improve AR will necessarily ameliorate outcome. This requires scrutiny in prospective studies. This study employed TOE rather than angiography to stratify none/trivial, intermediate and severe AR, as is the present convention in the USA, and then haemodynamics to stratify further the intermediate AR. Validation of its incremental value in patients whose AR is first stratified using angiography rather than TOE, as is commonplace in Europe, is merited.
Conclusions
Although presently echocardiography is the preferred modality for the assessment of paravalvular regurgitation after TAVI in clinical trials, it is unreliable as a prognostic index when it is in the intermediate range. Diastolic haemodynamic parameters, although valuable, are dramatically influenced by heart rate such that relative bradycardia or tachycardia greatly diminishes their prognostic value. A composite heart-rate-adjusted haemodynamic-echocardiographic aortic insufficiency (CHAI) score offers a considerable improvement in the stratification of risk of paravalvular regurgitation, improving on both echocardiographic grading and non-heart-rate-adjusted haemodynamic parameters.

Impact on daily practice
In this study, prognostication of post-TAVI paravalvular aortic regurgitation (PVAR) in the intermediate range of echocardiographic severity was found to be unreliable and was greatly enhanced by the integration of heart-rate-adjusted transcatheter haemodynamics. Additional manoeuvres to ameliorate paravalvular regurgitation may themselves contribute to adverse events after TAVI and decisions to treat or not to treat acutely may be incorrectly guided by echocardiography or transcatheter haemodynamics without heart-rate adjustment. The presented data support the routine incorporation of heart-rate-adjusted haemodynamics to tailor daily practice in the setting of mild or moderate PVAR.

Acknowledgements
We acknowledge the valued contribution of Mitch Gheorghiu, Jasmina Stegic, Tracy Salseth, Heera Pokhrel and Jigarkumar Patel to our clinical research programme.

Conflict of interest statement
H. Jilaihawi is a consultant to Edwards Lifesciences, St. Jude Medical and Venus Medtech. O. Sadruddin is an employee of St. Jude Medical. R. Siegel is a consultant to Edwards Lifesciences. R. Makkar has received grant support from Edwards Lifesciences and St. Jude Medical, is a consultant to Abbott Vascular, Cordis, and Medtronic, and holds equity in Entourage Medical. The other authors have no conflicts of interest to declare.

References


**Online data supplement**

**Online Appendix 1.** Statistical methods.

**Online Table 1.** Receiver operator characteristic analyses of haemodynamic parameters with one-year mortality as the endpoint.

**Online Figure 1.** Kaplan-Meier survival curves according to immediate post-TAVI haemodynamic data. Heart rate adjustment improves the stratification of survival by DD but not ARi.
Online data supplement

Online Appendix 1. Statistical methods.

ROC curves were generated using post-TAVI one-year mortality as the endpoint (state variable) and VARC-2 TOE AR grade, CAI score and CHAI score as the studied variables. The method of DeLong et al10 was used for direct comparisons of the discriminatory value of one modality to another. Kaplan-Meier curves were also studied for one-year survival stratified according to these respective groups.

A multivariable model for one-year mortality incorporating baseline and periprocedural variables associated with one-year mortality to a significance ≤0.1 was employed using a Forward: LR analysis. This included age, male sex, baseline creatinine >2 mg/dL, pulmonary disease, STS score, baseline peak velocity, heart rate and LV ejection fraction. In order to establish further the dominant prognostic modality assessing PVAR, the three competing parameters PVAR ≥ moderate by TOE, CAI score ≥2 and CHAI score ≥2 were progressively added to the model.

Online Table 1. Receiver operator characteristic analyses of haemodynamic parameters with one-year mortality as the endpoint.

<table>
<thead>
<tr>
<th></th>
<th>All patients (n=303)</th>
<th>95% Confidence interval</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Area</td>
<td>Lower</td>
<td>Upper</td>
</tr>
<tr>
<td>Post-TAVI AoDBP</td>
<td>0.59</td>
<td>0.50</td>
<td>0.67</td>
</tr>
<tr>
<td>-LVEDP</td>
<td>0.58</td>
<td>0.49</td>
<td>0.66</td>
</tr>
<tr>
<td>Post-TAVI AoSBP</td>
<td>0.61</td>
<td>0.53</td>
<td>0.69</td>
</tr>
<tr>
<td>ARi</td>
<td>0.60</td>
<td>0.52</td>
<td>0.68</td>
</tr>
<tr>
<td>HRA-ARi (HR 80)</td>
<td>0.63</td>
<td>0.55</td>
<td>0.71</td>
</tr>
<tr>
<td>DD</td>
<td>0.64</td>
<td>0.56</td>
<td>0.72</td>
</tr>
<tr>
<td>HRA-DD (HR 80)</td>
<td>0.68</td>
<td>0.60</td>
<td>0.76</td>
</tr>
</tbody>
</table>

ARi: aortic regurgitation index; AoDBP: aortic diastolic blood pressure; AoSBP: aortic systolic blood pressure; DD: diastolic delta; HR: heart rate; HRA: heart-rate-adjusted; LVEDP: left ventricular end-diastolic blood pressure; TAVI: transcatheter aortic valve implantation

Online Figure 1. Kaplan-Meier survival curves according to immediate post-TAVI haemodynamic data. Kaplan-Meier survival curves are shown for a stratification of transcatheter haemodynamics using the ARi without heart-rate adjustment, panel A(i), and with heart-rate adjustment, panel A(ii), and using the DD without heart-rate adjustment, panel B(i), and with heart-rate adjustment, panel B(ii). Heart-rate adjustment improves the stratification of survival by DD but not ARi.